ClinicalTrials.Veeva

Menu

Lifestyle Interventions to Improve Glycemic Parameters and Reduce Gestational Diabetes in High-risk Pregnant Individuals

Indiana University logo

Indiana University

Status

Begins enrollment in 5 months

Conditions

Gestational Diabetes
Pregnancy Complications

Treatments

Behavioral: GDM Prevention Program

Study type

Interventional

Funder types

Other

Identifiers

NCT06445270
PREVENT-GDM

Details and patient eligibility

About

The goal of this study is assess the impact of a higher intensity dietary and activity counseling program to improve blood sugar control and reduce the chance of developing gestational diabetes (GDM) as compared to the current standard diet and activity counseling.

Full description

GDM is associated with adverse maternal and newborn outcomes, as well as potential lifelong consequences. Currently, clinical guidelines recommend screening for pre-existing Type 2 diabetes mellitus at new obstetric visits for individuals at high risk of developing GDM. For those who do not screen positive, but still may be at risk for GDM, standard practice is for basic diet, exercise, and weight gain counseling.

In this study, eligible participants will be randomized into one of two groups: usual care with standard diet and exercise counseling or a GDM prevention program that consists of a more intensive exercise and monitoring program.

All participants will be asked to wear an activity tracker and continuous glucose monitors (CGMs) at specified time points throughout their pregnancy. Blood will be drawn at specified time points to measure hemoglobin A1c, lipids, and HOMA-IR measures.

Enrollment

100 estimated patients

Sex

Female

Ages

14+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Gestational age less or equal to 16 + 6 weeks confirmed via ACOG dating guidelines AND one of the following
  • 35 years of age or older
  • Family history of first degree relative with diabetes mellitus
  • Body Mass Index (BMI) greater than or equal to 30
  • Hemoglobin A1c value between 5.9% to 6.4%

Exclusion criteria

  • Multiple gestations
  • Current diagnosis of Type 1 or 2 diabetes mellitus including a diagnosis during this pregnancy
  • Pre-pregnancy chronic (>2 weeks) usage of systemic steroids (inhaled and short term usage acceptable)
  • Planned pregnancy termination
  • Currently taking or took 3 months prior to conception Metformin
  • Unable to provide informed consent in English or Spanish
  • Major fetal anomalies listed below that are known prior to enrollment.

Major fetal anomalies:

  • Congenital diaphragmatic hernia
  • Congenital cystic adenomatoid malformation
  • Pleural effustions
  • Chylothorax
  • Bronchogenic cyst
  • Bronchopulmonary sequestration
  • Anomalous pulmonary venous return
  • Tricuspid atresia
  • Mitral atresia
  • Double right ventricle
  • Ebstein's malformation
  • Pulmonary atresia
  • Hypoplastic left heart syndrome
  • Aortic coarctation
  • Fetal arrhythmias
  • Transposition of the great vessels
  • Tetrology of Fallot
  • Double outlet right ventricle
  • Aortic stenosis
  • Holoprosencephaly
  • Anencephaly
  • Dandy-Walker malformation or variant
  • Septo-optic dysplasia
  • Neural tube defect
  • Vein of Galen aneurysm
  • Bilateral renal agenesis
  • Cystic renal disease
  • Obstructive uropathy
  • Horseshoe kidney
  • Megacystis microcolon
  • Cloacal abnormality
  • Achondrogenesis
  • Thanatophoric dysplasia
  • Thoracic dysplasia
  • Osteogenesis imperfecta
  • Short rib polydacyly
  • Any skeletal defect with suspected small thorax
  • Hypophosphatemia
  • Any karyotypic abnormality
  • Any suspected genetic syndrome
  • Cleft lip/palate
  • Micrognathia
  • Hydrops
  • Fetal anemia (<35% on cordocentesis)
  • Neck mass
  • Gastroschsis
  • Omphalocele

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

100 participants in 2 patient groups

Control
No Intervention group
Description:
This arm consists of standard of care counseling for diet and exercise.
GDM Prevention Program
Experimental group
Description:
This arm consists of a more intensive exercise and monitoring program. .
Treatment:
Behavioral: GDM Prevention Program

Trial contacts and locations

1

Loading...

Central trial contact

David M Haas, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems